@article{1a7edfddd41c49208d71de405bcb67ee,
title = "Multisite concordance of DSC-MRI analysis for brain tumors: Results of a National Cancer Institute Quantitative Imaging Network Collaborative Project",
abstract = "BACKGROUND AND PURPOSE: Standard assessment criteria for brain tumors that only include anatomic imaging continue to be insufficient. While numerous studies have demonstrated the value of DSC-MR imaging perfusion metrics for this purpose, they have not been incorporated due to a lack of confidence in the consistency of DSC-MR imaging metrics across sites and platforms. This study addresses this limitation with a comparison of multisite/multiplatform analyses of shared DSC-MR imaging datasets of patients with brain tumors. MATERIALS AND METHODS: DSC-MR imaging data were collected after a preload and during a bolus injection of gadolinium contrast agent using a gradient recalled-echo–EPI sequence (TE/TR 30/1200 ms; flip angle 72°). Forty-nine low-grade (n 13) and high-grade (n 36) glioma datasets were uploaded to The Cancer Imaging Archive. Datasets included a predetermined arterial input function, enhancing tumor ROIs, and ROIs necessary to create normalized relative CBV and CBF maps. Seven sites computed 20 different perfusion metrics. Pair-wise agreement among sites was assessed with the Lin concordance correlation coefficient. Distinction of low- from high-grade tumors was evaluated with the Wilcoxon rank sum test followed by receiver operating characteristic analysis to identify the optimal thresholds based on sensitivity and specificity. RESULTS: For normalized relative CBV and normalized CBF, 93% and 94% of entries showed good or excellent cross-site agreement (0.8 Lin concordance correlation coefficient 1.0). All metrics could distinguish low- from high-grade tumors. Optimum thresholds were determined for pooled data (normalized relative CBV 1.4, sensitivity/specificity 90%:77%; normalized CBF 1.58, sensitivity/specificity 86%:77%). CONCLUSIONS: By means of DSC-MR imaging data obtained after a preload of contrast agent, substantial consistency resulted across sites for brain tumor perfusion metrics with a common threshold discoverable for distinguishing low- from high-grade tumors.",
author = "Schmainda, {K. M.} and Prah, {M. A.} and Rand, {S. D.} and Y. Liu and B. Logan and M. Muzi and Rane, {S. D.} and X. Da and Yen, {Y. F.} and J. Kalpathy-Cramer and Chenevert, {T. L.} and B. Hoff and B. Ross and Y. Cao and Aryal, {M. P.} and B. Erickson and P. Korfiatis and T. Dondlinger and L. Bell and L. Hu and Kinahan, {P. E.} and Quarles, {C. C.}",
note = "Funding Information: Disclosures: Kathleen M. Schmainda—RELATED: Grant: National Institutes of Health/National Cancer Institute, Comments: U01 176110, R01 CA082500*; UNRELATED: Grants/Grants Pending: National Institutes of Health, Comments: National Institutes of Health grants submitted on various topics*; Other: Imaging Biometrics, Comments: ownership interest. Ying Liu—UNRELATED: Employment: Medical College of Wisconsin*; Grants/Grants Pending: National Institutes of Health.* Jayashree Kalpathy-Cramer—RELATED: Grant: National Institutes of Health, Comments: National Institutes of Health/National Cancer Institute grants U24CA180927, U24CA180918, U01CA154601*; UNRELATED: Consultancy: INFOTECHsoft; Grants/ Grants Pending: National Institutes of Health/National Science Foundation, Comments: R01EY019474-05 National Science Foundation.* Thomas L. Chenevert—RELATED: Grant: National Institutes of Health*; UNRELATED: Grants/Grants Pending: National Institutes of Health*; Patents (Planned, Pending or Issued): University of Michigan*; Royalties: University of Michigan.* Benjamin Hoff—RELATED: Grant: National Institutes of Health, Comments: U01 CA085878.* Brian Ross—RELATED: Grant: National Institutes of Health, Comments: This was part of an National Institutes of Health grant to the University of Michigan.* Yue Cao—RELATED: Grant: National Institutes of Health.* Panagiotis Korfiatis—RELATED: Grant: National Cancer Institute, Comments: CA160045.* Bradley Erickson—RELATED: Grant: National Cancer Institute, Comments: CA160045.* C.C. Quarles—RELATED: Grant: National Cancer Institute.* Laura Bell—RELATED: Grant: National Institutes of Health/National Cancer Institute R01 CA158079.* Timothy Dondlinger—RELATED: Grant: National Institutes of Health*; UNRELATED: Employment: Imaging Biometrics LLC. P.E. Kinahan—RELATED: Grant: GE Healthcare, Comments: research grant*; Other: cofounder of PET/X LLX.* *Money paid to the Institution. Funding Information: This work was supported by the National Institutes of Health/National Cancer Institute: U01 CA176110 (K.M.S., M.A.P., S.D.R., T.D.), U01 CA148131 (M.M., P.E.K.), U01 CA166104 (T.L.C., B.H.), U01 CA154601 (X.D., Y.-F.Y., J.K.-C.), U01 CA160045 (B.E., P.K.), U01 CA 183848 (Y.C., M.P.A.), R01 CA158079 (L.B., C.C.Q.), R01 CA082500 (K.M.S., M.A.P., S.D.R.), R50 CA211270 (M.M.), and P01 CA085878, U24CA180927, U24CA180918 (J.K.-C.).",
year = "2018",
month = jun,
day = "1",
doi = "10.3174/ajnr.A5675",
language = "English (US)",
volume = "39",
pages = "1008--1016",
journal = "American Journal of Neuroradiology",
issn = "0195-6108",
publisher = "American Society of Neuroradiology",
number = "6",
}